Role of A(2A) receptor in the modulation of myocardial reperfusion damage

Anna Cargnoni, Claudio Ceconi, Antonella Boraso, Palmira Bernocchi, Angela Monopoli, Salvatore Curello, Roberto Ferrari

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Adenosine protects myocardium from ischemia and reperfusion damage; however, the mechanism of action is still under discussion. We investigated whether (a) adenosine protects isolated crystalloid-perfused rabbit heart from ischemia/reperfusion injury; (b) this action is receptor mediated and what receptor subtypes are involved, and (c) this action is dependent on an enhanced nitric oxide production. Our results showed a cardioprotective effect of adenosine (10-4 M), of nonselective adenosine-receptor agonist 5'-N-ethyl-carboxamidoadenosine (NECA; 5 x 10-6 M), and of A(2A) agonists CGS 21680 (10-8 and 10-6 M), 2-hexynylNECA (10-7 M). On the contrary, A1 agonist CCPA (10-8 and 10-6 M) does not provide any protection. The effect has been achieved in terms of significant reduction in contracture development during reperfusion [diastolic pressure was 46.8 ± 7.1 mm Hg (p <0.01); 46.1 ± 7.8 mm Hg (p <0.01); 46.9 ± 5.5 mm Hg (p <0.01); and 59.3 ± 6.7 mm Hg (p <0.05) with 10-4 M adenosine, 5 x 10-6 M NECA, 10-6 M CGS 21680, and 10-7 M 2-hexynylNECA, respectively, versus 77.6 ± 5.0 mm Hg in control]; reduced creatine phosphokinase release (13.5 ± 1.6, 22.2 ± 7.9, 14.2 ± 3.3, and 14.1 ± 4.5 U/gww in treated hearts vs. 34.6 ± 7.2 U/gww in controls; p <0.05); improved energy metabolism [adenosine triphosphate (ATP) content is 9.9 ± 0.5, 10.4 ± 0.6, 9.8 ± 0.5, and 10.5 ± 0.5 μmol/gdw in treated hearts vs. 7.6 ± 0.2 μmol/gdw; p <0.05]. Moreover, our data indirectly show a functional presence of A(2A) receptors on cardiomyocytes as the protection is A(2A) mediated and exerted only during reperfusion, although in the absence of blood and coronary flow changes. These activities appear independent of nitric oxide pathways, as adenosine and 2-hexynylNECA effects are not affected by the presence of a nitric oxide- synthase inhibitor (10-4 M L-NNA).

Original languageEnglish
Pages (from-to)883-893
Number of pages11
JournalJournal of Cardiovascular Pharmacology
Volume33
Issue number6
DOIs
Publication statusPublished - Jun 1999

Fingerprint

Myocardial Reperfusion
Reperfusion Injury
Adenosine
Adenosine-5'-(N-ethylcarboxamide)
Reperfusion
Nitric Oxide
Purinergic P1 Receptor Agonists
Contracture
Creatine Kinase
Cardiac Myocytes
Nitric Oxide Synthase
Energy Metabolism
Myocardium
Ischemia
Adenosine Triphosphate
Rabbits
Blood Pressure

Keywords

  • A(2A) agonists
  • Adenosine
  • Myocardial reperfusion damage

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Role of A(2A) receptor in the modulation of myocardial reperfusion damage. / Cargnoni, Anna; Ceconi, Claudio; Boraso, Antonella; Bernocchi, Palmira; Monopoli, Angela; Curello, Salvatore; Ferrari, Roberto.

In: Journal of Cardiovascular Pharmacology, Vol. 33, No. 6, 06.1999, p. 883-893.

Research output: Contribution to journalArticle

Cargnoni, Anna ; Ceconi, Claudio ; Boraso, Antonella ; Bernocchi, Palmira ; Monopoli, Angela ; Curello, Salvatore ; Ferrari, Roberto. / Role of A(2A) receptor in the modulation of myocardial reperfusion damage. In: Journal of Cardiovascular Pharmacology. 1999 ; Vol. 33, No. 6. pp. 883-893.
@article{8b001fd4f66549e7b2ddfdac21870661,
title = "Role of A(2A) receptor in the modulation of myocardial reperfusion damage",
abstract = "Adenosine protects myocardium from ischemia and reperfusion damage; however, the mechanism of action is still under discussion. We investigated whether (a) adenosine protects isolated crystalloid-perfused rabbit heart from ischemia/reperfusion injury; (b) this action is receptor mediated and what receptor subtypes are involved, and (c) this action is dependent on an enhanced nitric oxide production. Our results showed a cardioprotective effect of adenosine (10-4 M), of nonselective adenosine-receptor agonist 5'-N-ethyl-carboxamidoadenosine (NECA; 5 x 10-6 M), and of A(2A) agonists CGS 21680 (10-8 and 10-6 M), 2-hexynylNECA (10-7 M). On the contrary, A1 agonist CCPA (10-8 and 10-6 M) does not provide any protection. The effect has been achieved in terms of significant reduction in contracture development during reperfusion [diastolic pressure was 46.8 ± 7.1 mm Hg (p <0.01); 46.1 ± 7.8 mm Hg (p <0.01); 46.9 ± 5.5 mm Hg (p <0.01); and 59.3 ± 6.7 mm Hg (p <0.05) with 10-4 M adenosine, 5 x 10-6 M NECA, 10-6 M CGS 21680, and 10-7 M 2-hexynylNECA, respectively, versus 77.6 ± 5.0 mm Hg in control]; reduced creatine phosphokinase release (13.5 ± 1.6, 22.2 ± 7.9, 14.2 ± 3.3, and 14.1 ± 4.5 U/gww in treated hearts vs. 34.6 ± 7.2 U/gww in controls; p <0.05); improved energy metabolism [adenosine triphosphate (ATP) content is 9.9 ± 0.5, 10.4 ± 0.6, 9.8 ± 0.5, and 10.5 ± 0.5 μmol/gdw in treated hearts vs. 7.6 ± 0.2 μmol/gdw; p <0.05]. Moreover, our data indirectly show a functional presence of A(2A) receptors on cardiomyocytes as the protection is A(2A) mediated and exerted only during reperfusion, although in the absence of blood and coronary flow changes. These activities appear independent of nitric oxide pathways, as adenosine and 2-hexynylNECA effects are not affected by the presence of a nitric oxide- synthase inhibitor (10-4 M L-NNA).",
keywords = "A(2A) agonists, Adenosine, Myocardial reperfusion damage",
author = "Anna Cargnoni and Claudio Ceconi and Antonella Boraso and Palmira Bernocchi and Angela Monopoli and Salvatore Curello and Roberto Ferrari",
year = "1999",
month = "6",
doi = "10.1097/00005344-199906000-00008",
language = "English",
volume = "33",
pages = "883--893",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Role of A(2A) receptor in the modulation of myocardial reperfusion damage

AU - Cargnoni, Anna

AU - Ceconi, Claudio

AU - Boraso, Antonella

AU - Bernocchi, Palmira

AU - Monopoli, Angela

AU - Curello, Salvatore

AU - Ferrari, Roberto

PY - 1999/6

Y1 - 1999/6

N2 - Adenosine protects myocardium from ischemia and reperfusion damage; however, the mechanism of action is still under discussion. We investigated whether (a) adenosine protects isolated crystalloid-perfused rabbit heart from ischemia/reperfusion injury; (b) this action is receptor mediated and what receptor subtypes are involved, and (c) this action is dependent on an enhanced nitric oxide production. Our results showed a cardioprotective effect of adenosine (10-4 M), of nonselective adenosine-receptor agonist 5'-N-ethyl-carboxamidoadenosine (NECA; 5 x 10-6 M), and of A(2A) agonists CGS 21680 (10-8 and 10-6 M), 2-hexynylNECA (10-7 M). On the contrary, A1 agonist CCPA (10-8 and 10-6 M) does not provide any protection. The effect has been achieved in terms of significant reduction in contracture development during reperfusion [diastolic pressure was 46.8 ± 7.1 mm Hg (p <0.01); 46.1 ± 7.8 mm Hg (p <0.01); 46.9 ± 5.5 mm Hg (p <0.01); and 59.3 ± 6.7 mm Hg (p <0.05) with 10-4 M adenosine, 5 x 10-6 M NECA, 10-6 M CGS 21680, and 10-7 M 2-hexynylNECA, respectively, versus 77.6 ± 5.0 mm Hg in control]; reduced creatine phosphokinase release (13.5 ± 1.6, 22.2 ± 7.9, 14.2 ± 3.3, and 14.1 ± 4.5 U/gww in treated hearts vs. 34.6 ± 7.2 U/gww in controls; p <0.05); improved energy metabolism [adenosine triphosphate (ATP) content is 9.9 ± 0.5, 10.4 ± 0.6, 9.8 ± 0.5, and 10.5 ± 0.5 μmol/gdw in treated hearts vs. 7.6 ± 0.2 μmol/gdw; p <0.05]. Moreover, our data indirectly show a functional presence of A(2A) receptors on cardiomyocytes as the protection is A(2A) mediated and exerted only during reperfusion, although in the absence of blood and coronary flow changes. These activities appear independent of nitric oxide pathways, as adenosine and 2-hexynylNECA effects are not affected by the presence of a nitric oxide- synthase inhibitor (10-4 M L-NNA).

AB - Adenosine protects myocardium from ischemia and reperfusion damage; however, the mechanism of action is still under discussion. We investigated whether (a) adenosine protects isolated crystalloid-perfused rabbit heart from ischemia/reperfusion injury; (b) this action is receptor mediated and what receptor subtypes are involved, and (c) this action is dependent on an enhanced nitric oxide production. Our results showed a cardioprotective effect of adenosine (10-4 M), of nonselective adenosine-receptor agonist 5'-N-ethyl-carboxamidoadenosine (NECA; 5 x 10-6 M), and of A(2A) agonists CGS 21680 (10-8 and 10-6 M), 2-hexynylNECA (10-7 M). On the contrary, A1 agonist CCPA (10-8 and 10-6 M) does not provide any protection. The effect has been achieved in terms of significant reduction in contracture development during reperfusion [diastolic pressure was 46.8 ± 7.1 mm Hg (p <0.01); 46.1 ± 7.8 mm Hg (p <0.01); 46.9 ± 5.5 mm Hg (p <0.01); and 59.3 ± 6.7 mm Hg (p <0.05) with 10-4 M adenosine, 5 x 10-6 M NECA, 10-6 M CGS 21680, and 10-7 M 2-hexynylNECA, respectively, versus 77.6 ± 5.0 mm Hg in control]; reduced creatine phosphokinase release (13.5 ± 1.6, 22.2 ± 7.9, 14.2 ± 3.3, and 14.1 ± 4.5 U/gww in treated hearts vs. 34.6 ± 7.2 U/gww in controls; p <0.05); improved energy metabolism [adenosine triphosphate (ATP) content is 9.9 ± 0.5, 10.4 ± 0.6, 9.8 ± 0.5, and 10.5 ± 0.5 μmol/gdw in treated hearts vs. 7.6 ± 0.2 μmol/gdw; p <0.05]. Moreover, our data indirectly show a functional presence of A(2A) receptors on cardiomyocytes as the protection is A(2A) mediated and exerted only during reperfusion, although in the absence of blood and coronary flow changes. These activities appear independent of nitric oxide pathways, as adenosine and 2-hexynylNECA effects are not affected by the presence of a nitric oxide- synthase inhibitor (10-4 M L-NNA).

KW - A(2A) agonists

KW - Adenosine

KW - Myocardial reperfusion damage

UR - http://www.scopus.com/inward/record.url?scp=0032587880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032587880&partnerID=8YFLogxK

U2 - 10.1097/00005344-199906000-00008

DO - 10.1097/00005344-199906000-00008

M3 - Article

C2 - 10367591

AN - SCOPUS:0032587880

VL - 33

SP - 883

EP - 893

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -